Gain Therapeutics reports FY2023 net loss of $22.3M; cash runway into Q1 2025

Gain Therapeutics, Inc.

Net loss for FY2023 was $22.3M ($1.71 per share), vs $17.6M ($1.48) in FY2022.
R&D expenses rose to $11.5M from $8.4M due to Phase 1 trial of GT-02287 for GBA1 Parkinson's disease.
Cash and marketable securities $16.8M as of Dec 31, 2023; expected to fund operations into Q1 2025.
Initiated MAD part of Phase 1 trial of GT-02287; data presented at AD/PD 2024 and WORLD Symposium.
Raised $10.1M gross proceeds from public offering and private placement in 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Gain Therapeutics, Inc. reported the year ended December 31, 2023 results: net income $22.3 million, EPS $1.71.

Period: the year ended December 31, 2023
Net income: $22.3 million
EPS: $1.71
Result: reported results

Exact text from the filing

Net loss for the year ended December 31, 2023 was $22.3 million, compared to a net loss of $17.6 million for the year ended December 31, 2022.

View on SEC.gov

326 earnings releases filed in the last 30 days. Browse all earnings releases →

Gain Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-24-003940

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.